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ABSTRACT 
Objective: A new, simple and sensitive spectrophotometric method has been developed for the determination of some antidepressant drugs, 
namely desvenlafaxine (DSV), dapoxetine (DAP) and citalopram (CIT) in pharmaceutical formulations. 
Methods: The proposed method was based on the formation of yellow colored ion-pair complex between the studied drugs and two sulpho 
phthalein dyes viz., bromophenol blue (BPB), and bromothymol blue (BTB) in acidic medium. The optimizations of the reaction conditions were 
investigated. Beer’s law limits, Sandell’s sensitivity, correlation coefficient, detection, and quantification limits were calculated. 
Results: The formed complexes showed absorption maxima at 412 nm and 410 nm measured for all the drugs with BPB and BTB, respectively. The 
Job’s method of continuous variations indicated that a single l: l ion-pair complex was formed. Calibration curves were linear over the concentration 
range of 0.8–11.4, 0.8–6.4 and 0.8–8.0 μg/ml for DSV, DAP and CIT, respectively.  
Conclusion: The proposed method has been applied successfully for the analysis of the investigated drugs in pure and in their dosage forms. No 
interference was observed from common excipients present in pharmaceutical formulations. The proposed method is suitable for quality control 
applications. 
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INTRODUCTION  
Desvenlafaxine succinate is a newer antidepressant drug, which is 
chemically 1-[(1RS)-2-(Dimethylamino)-1-(4-hydroxyphenyl) ethyl] 
cyclohexanol succinate monohydrate (DSV, fig. 1a). Desvenlafaxine 
succinate is a structurally novel SNRI (serotonin-norepinephrine 
reuptake inhibitor) useful for the treatment of MDD (major 
depressive disorder). Desvenlafaxine (O-desmethyl-venlafaxine) is 
the major active metabolite of the antidepressant venlafaxine, a 
medication used to treat major depressive, generalized anxiety and 
panic disorders. Literature survey reveals HPLC coupled to 
spectrophotometric [1–3], spectrofluorimetric [4–6] or coulometric 
detection [7], capillary electrophoresis [8–11], adsorptive stripping 
voltammetric [12], HPLC-ESI/MS [13] and LC-MS/MS [14–17] have been 
used. Desvenlafaxine succinate is not official in any pharmacopoeia. 
Dapoxetine HCl (DAP, fig. 1b) is designated chemically as (S)-N, N-
dimethyl-3-(naphthalen-1-yloxy)-1 phenylpropan-1-amine. This 
drug is mainly useful in erectile dysfunction as selective serotonin 
reuptake inhibitor (SSRI) [18]. SSRI's are a class of compounds 
typically used as antidepressants in the treatment of depression, 
anxiety disorders, and some personality disorders. They can also 
sometimes be effective and used in treating premature ejaculation 
problems, impotence and some cases of insomnia. The drug’s 
mechanism of action is thought to be related to inhibition of neuronal 
reuptake of serotonin and subsequent potentiation of serotonin 
activity and increase the ejaculation time [19]. The literature study 
reveals that several UV spectrometric and chromatographic methods 
available for dapoxetine in combined tablet formulation [20–27]. No 
method has been reported for individual dapoxetine HCl using visible 
spectrophotometric methods. 
Citalopram, (CIT, fig. 1c) 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl) 
-1, 3-dihydroisobezofuran-5-carbonitrile [28], is a second generation 
antidepressant and one of the recently introduced SSRIs. It is used 
for managing depression, social anxiety disorder, panic disorder, and 
obsessive-compulsive disorder [29–31]. Several methods have been 
devised for the determination of citalopram in pharmaceutical 
preparations and biological fluids. These include high performance 
liquid chromatography (HPLC) with UV detectors [32–34], HPLC 
with fluorescence detectors [35–37], HLPC/mass spectrometry [38–
40], gas chromatography [41, 42], electrophoretic methods [43–45] 
and spectrophotometric [46–48] methods. However, few 
spectrofluorimetric [49, 50] methods have been reported in the 
literature, and most reported methods involve multistep procedures 
and have poor selectivity's and sensitivities. 
Our present study has been designed to describe a simple, accurate, 
rapid and precise spectrophotometric methods for the deter-
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Fig. 1: Chemical structure of the investigated drugs 
 
MATERIALS AND METHODS 
Apparatus 
All the absorbance spectral measurements were made using 
spectroscan 80 D double-beam UV/Visible spectrophotometer 
(Biotech Engineering Ltd. (UK), with wavelength range 190 nm ~ 
1100 nm, spectral bandwidth 2.0 nm, with 10 mm matched quartz 
cells. The pH values of buffer solutions were measured using Jenway 
instrument pH-meter (combined electrode). 
Reagents and solutions 
All of the chemicals used were of analytical or pharmaceutical grade 
and used without further purification. Distilled water was used to 
prepare all solutions.  
i. A 1.0×10-3M of bromophenol blue and bromothymol blue (Aldrich 
Co., Ltd., Gillingham-Dorst, Germany), were prepared by dissolving 
66.996 mg and 62.438 mg from each dye in 2 ml methanol then, add 
20 ml distilled water and diluted to 100 ml in a calibrated flask with 
distilled water to the mark. 
ii. Series of buffer solutions of KCl-HCl (pH 1.0-2.2), NaOAc-HCl (2.2-6.8) 
and NaOAc-AcOH (3.4-5.6) pH were prepared by standard methods. 
iii. A pharmaceutical grade of DSV, DAP and CIT certified to be 
99.85% pure was obtained as a gift were kindly supplied from 
Egyptian International Pharmaceutical Industries Company 
(EIPICo), Egypt. Stock solutions of pure DSV, DAP and CIT were 
prepared separately by dissolving accurately weighed 10 mg of each 
drug in distilled water and finally the volume was made up to 100 ml 
with distilled water (100 μg/ml).  
General recommended procedures 
Into a series of separated funnels, accurately measured aliquots of 
DSV, DAP and CIT, in the concentration range shown in (table 1) 
were pitted out. A volume of 2.0 ml of 1×10-3M BPB or BTB were 
added. Then, 2.0 ml of buffer solution of pH = 2 for each system was 
added, and the volume was completed to 10 ml with distilled water. 
The ion-pairs were extracted with 10 ml of dichloromethane by 
shaking for 2.0 min and then, the combined dichloromethane 
extracts were dried over anhydrous sodium sulphate. The 
absorbance of colored ion-pair complexes was measured within 30 
min of extraction against a reagent blank prepared in the same 
manner except the addition of drugs. In both the methods, a 
standard curve was prepared by plotting the increasing absorbance 
values versus concentrations of the drug. A linear equation for the 
standard curve was calculated by linear regression. 
Procedure for tablets 
At least ten tablets of the drugs were weight into a small dish, 
powdered and mixed well. A portion equivalent to 10 mg of DSV, 
DAP and CIT were weight and dissolved in distilled water, filtered 
into a 100 ml calibrated flask and diluted to volume with water. 
Solutions of working range concentration were prepared by proper 
dilution of this stock solution with water and followed the above 
procedure for the calibration curve. 
RESULTS AND DISCUSSION 
Absorption spectra of the yellow color of the studied drugs with BPB 
or BTB ion-pair complex with a maximum absorbance (λmax) at 412 
and 410 nm, respectively is shown in fig. 2. The measurements were 
made at these wavelengths for bulk and tablet samples. The studied 
drugs contain a tertiary amino group which is protonated in the acid 
medium while the sulphonic acid group is present in BPB and BTB 
that is the only group undergoing dissociation in the pH range 1.0–
5.0. The color of such dyes is due to the opening of lactoid ring and 
subsequent formation of the quinoid group. It is supposed that the 
two tautomers are present in equilibrium but due to strong acidic 
nature of the sulphonic acid group, the quinoid body must 
predominate. Finally the protonated drug forms ion-pairs with the 
dyestuffs which are quantitatively extracted into dichloromethane [51, 
52]. The suggested reaction pathway for the reaction product of DSV–
BPB ion–pair complex formation, for example, is given in Scheme 1. 
 
 
Fig. 2: Absorption spectra of ion-pair complexes of: A-CIT (4 
µg/ml), B-DSV (6.4 µg/ml) and C-DPA (5.2 µg/ml) with BPB 
 
Optimization of the reaction conditions 
The optimum reaction conditions for determination of the ion-pair 
complexes were established. Then linearity, accuracy, precision, 
sensitivity, and stability of proposed methods were described and 
these developed methods applied to pharmaceutical preparations as 
tablets and obtained results evaluated statistically. 
Effect of buffer type and pH 
It was observed that the effective extraction of the complex depends 
on the type of buffer used and its pH. The effect of pH was studied by 
extracting the colored complexes in the presence of various buffers 
such as KCl–HCl (pH 1.0–2.2), NaOAc–HCl (pH 2.2–6.8) and NaOAc–
AcOH (pH 3.6–5.6). It is evident that the maximum color intensity 
and maximum absorbance were found in KCl–HCl buffer at pH = 2 
for both DSV, DAP and CIT (fig. 3, 4). Buffer volume was determined 
by applying the same experiment and variation the volume regularly 
(0.5–5.0 ml). The higher absorbance value obtained at using 2.0 ml 
of buffer solutions. 
Effect of reagent concentration 
The DSV, DAP and CIT concentrations were kept constant, while the 
concentrations of BPB or BTB was varied from 0.5–4.0 ml of 1.0×10-
3M. The results showed that the absorbance of the extracted ion-
pairs increased by increasing the BPB or BTB concentrations till 1.0 
ml. After this volume, the absorbance remains constant by 
increasing the volume of the reagents. So any excess of reagents has 
no effect on the determination of the drugs.  
Choice of organic solvents 
Different organic solvents as dichloromethane, carbon tetrachloride, 
chloroform and ether were tested as extractive solvents for the 
proposed method. Dichloromethane was preferred to other solvents 
for its selective and obtained the highest absorbance with 
dichloromethane. It was also observed that only one extraction was 
adequate to achieve a quantitative recovery of the complexes and 
the shortest time to reach the equilibrium between both phases. 
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Fig. 3: Effect of pH of buffer solution on the ion-pair complex 
formation between (11.4 µg/ml) ▪ DSV, (5.2 µg/ml) ● DAP and 
(8 µg/ml) ♦ CIT with 1.0×10-3M BPB 
 
 
Fig. 4: Effect of pH of buffer solution on the ion-pair complex 
formation between (8.0 µg/ml) ▪ DSV, (6.4 µg/ml) ● DAP and (8 
µg/ml) ♦ CIT with 1.0×10-3M BTB 
 Effect of temperature on the colored complexes 
The effect of temperature on colored complexes was studied over 
the range 20-50 °C. It was found that the absorbance of the ion-pair 
complex was constant up to 25 °C. At higher temperatures, the drug 
concentration was found to increase due to volatile nature of the 
dichloromethane. Therefore, the temperature chosen was 25 °C as 
the best temperature for determination of the investigated drugs in 
pure and pharmaceutical formulations. 
Effect of shaking time for extraction 
Shaking time ranging from 0.5-4.0 min was tested to ascertain the 
extraction of the complex. Maximum and constant absorbance value 
were obtained when extracted after 1.5 min shaking. Therefore, 
shaking time of 2.0 min was maintained throughout the experiment. 
Composition of the ion-pair complexes 
In order to establish the molar ratio between DSV, DAP and CIT on 
one side and BPB or BTB reagent used on the other, Job’s method of 
continuous variation was applied [53]. In this method, 5.0×10-4 M 
solutions of drugs and reagents were mixed in varying volume ratios 
in such a way that the total volume of each mixture was the same. 
The absorbance of each solution was measured and plotted against 
the mole fraction of the drug, [drug]/[drug]+[dyestuff] as shown in 
(fig. 5, 6). This measurement showed that 1: 1 complex was formed 
with each dyestuff.  
 
 
Fig. 5: Job’s method of continuous variation graph for the reaction 
of DSV, DAP and CIT with BPB, [drug] = [dye] = 5×10−4 M 
 
 
Fig. 6: Job’s method of continuous variation graph for the 




Under the optimum conditions described above, the calibration 
graphs were constructed for the investigated drugs. The molar 
absorptivity, Sandell̓s sensitivity, concentration range, regression 
equation and correlation coefficient for each drug are tabulated in 
(table 1). A linear relationship was found between the absorbance at 
λmax. Regression analysis of Beer’s law plotted at λmax reveals a good 
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correlation (fig. 7, 8). The graphs showed a negligible intercept, 
which was calculated by the least-squares method’s regression 
equation, A = a+bC (where A is the absorbance of 1.0 cm layer, b is 
the slope, a is the intercept and C is the concentration of the 
measured solution in µg/ml.  
The calculated molar absorptivity of drugs–BTB ion-pair complexes 
was found to be higher than the drugs–BPB ion-pair complexes. The 
limit of detection (LOD) and limit of quantitation (LOQ) are 
calculated according to ICH guidelines [54]. The results are as shown 
in (table 1). 
 
Table 1: Analytical parameters and optical characteristics of the proposed method 
Parameters BPB BTB 
DSV DAP CIT DSV DAP CIT 
λmax (nm) 412 412 412 410 410 410 
Beer’s law limit (µg/ml) 1.6–11.4 0.8–5.2 0.8–8.0 0.8–8.0 0.8–6.4 0.8–8.0 
Molar absorptivity(l mol-1 cm-1) 3.03×104 8.02×104 4.91×104 3.99×104 8.85×104 5.15×104 
Sandell’s sensitivity (ng/cm2) 8.682 4.262 6.605 6.611 3.862 6.298 
Correlation coefficient (r) 0.9994 1.000 0.9989 0.9993 1.000 0.9988 
Linear regression equation       
Sy/x 0.0111 3.21×10-3 0.0105 9.41×10-3 2.19×10-3 0.0115 
Intercept (a) 0.0795 -0.1195 0.0880 0.0716 0.1566 0.1234 
Slope (b) 0.1105 0.2692 0.1382 0.1506 0.1839 0.1446 
SD of slope (Sb) 1.78×10-3 1.92×10-3 3.13×10-3 2.81×10-3 6.56×10-3 3.43×10-3 
SD of intercept (Sa) 0.0111 3.70×10-3 9.77×10-3 8.76×10-3 2.04×10-3 0.0107 
Detection limits (µg/ml) 0.0483 0.0213 0.0679 0.0559 0.1070 0.0711 
Quantitation limits (µg/ml) 0.1611 0.0713 0.2264 0.1865 0.3567 0.2372 
A = a+bC, where A is the absorbance and C is the concentration of drug in µg/ml.  
 
 
Fig. 7: Calibration curve of ion-pair complexes of DSV, DAP and 
CIT with BPB against blank 
 
Accuracy and precision 
In order to determine the accuracy and precision of the 
recommended procedure five replicate determinations at three 
different concentrations of the studied drugs were carried out. 
Precision and accuracy were based on the calculated relative 
standard deviation (RSD, %) and relative error (RE, %) of the found 
concentration compared to the theoretical one, respectively and 
indicated that the proposed method is highly accurate and 
reproducible (tables 2, 3). 
 
 
Fig. 8: Calibration curve of ion-pair complexes of DSV, DAP and 
CIT with BTB against blank 
 
Table 2: Evaluation of accuracy and precision of the proposed method using BPB 





0.0138 6.471 -0.041 99.96 3.198 3.2 DSV 
7.9×10-3 1.926 -0.040 99.96 6.397 6.4 
0.011 1.876 -0.042 99.96 9.596 9.6 
0.0138 3.198 -0.041 99.96 6.471 3.2 DAP 
7.9×10-3 6.397 -0.041 99.96 1.926 6.4 
0.011 9.596 -0.041 99.96 1.876 9.6 
0.011 5.888 -0.043 99.96 1.599 1.6 CIT 
2.7×10-3 0.906 -0.061 99.94 3.997 4 
2.7×10-3 0.572 -0.041 99.96 6.397 6.4 
aMean value of five determinations., bRelative error., cRelative standard deviation. 
 
Analysis of dosage forms 
To evaluate the validity and reproducibility of the methods, known 
amounts of the DSV, DAP and CIT drugs were added to the 
previously analyzed pharmaceutical preparations and the mixtures 
were analyzed by the proposed methods. The percent recoveries are 
given in (Tables 4, 5). Interference studies revealed that the common 
excipients and other additives such as lactose, starch, gelatin, talc 
and magnesium trisilicate, that are usually present in the tablet 
dosage forms did not interfere at their regularly added levels. 
Didamony et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 6, 188-194 
 
192 
Table 3: Evaluation of accuracy and precision of the proposed method using BTB 
SE RSDc, % REb Recoverya, % Drug found µg/ml Drug taken µg/ml Drugs 
6.5×10-3 4.609 -0.062 99.94 1.599 1.6 DVS 
9.1×10-3 2.338 -0.081 99.92 4.796 4.8 
6.5 ×10-3 1.310 -0.061 99.94 6.396 6.4 
5.7×10-3 2.469 -0.050 99.95 1.5992 1.6 DAP 
0.0118 2.684 -0.025 99.97 3.1992 3.2 
7.2×10-3 1.272 -0.050 99.95 4.7976 4.8 
0.011 3.714 -0.062 99.94 1.599 1.6 CIT 
0.010 2.982 -0.041 99.96 3.998 4.0 
0.011 2.101 -0.040 99.96 6.397 6.4 
aMean value of five determinations., bRelative error., cRelative standard deviation. 
 
Table 4: Determination of the studied drugs in pharmaceutical preparation using BPB 
RSDc, % REb Recoverya, % Drug found µg/ml Drug taken µg/ml Drug  formulations 
1.112 -0.025 99.98 1.599 1.6 DVS 
(Prismaven, 100 mg)d 1.963 -0.06 99.94 3.997 4.0 
2.268 -0.061 99.94 6.396 6.4 
2.206 -0.025 99.97 1.599 1.6 DAP 
(Joypox 60 mg)e 2.105 -0.050 99.95 3.198 3.2 
2.416 -0.031 99.97 4.798 4.8 
1.961 -0.081 99.92 3.197 3.2 CIT 
(Cipramax, 40 mg)f 2.152 -0.041 99.96 6.397 6.4 
1.273 -0.060 99.94 9.594 9.6 
aMean value of five determinations, bRelative error, cRelative standard deviation, d,etength of ramdan for pharmaceutical industries, Egypt, fcopad 
egypt for trade and pharmaceutical industries, Egypt 
 













3.865 -0.081 99.92 1.598 1.6 DVS 
(Prismaven, 100 mg)d 1.152 -0.021 99.98 4.799 4.8 
1.550 -0.040 99.96 6.397 6.4 
1.814 -0.025 99.97 1.599 1.6 DAP 
(Joypox, 60 mg)e 2.521 -0.050 99.95 3.198 3.2 
2.029 -0.050 99.95 4.797 4.8 
1.724 -0.025 99.98 1.599  1.6 CIT 
(Cipramax, 40 mg)f 1.772 -0.040 99.96 3.998 4.0 
1.573 -0.011 99.99 6.399 6.4 
aMean value of five determinations., bRelative error., cRelative standard deviation., d,etength of ramdan for pharmaceutical industries, Egypt., fcopad 
egypt for trade and pharmaceutical industries, Egypt. 
 
CONCLUSION 
The proposed method is rapid, simple, accurate and in addition, offer 
advantages in the wide applicability of the new method for routine 
quality control is well established by the assay of DSV, DAP and CIT 
in pure form and in pharmaceutical preparations. Moreover, the 
method is free from interference by common additives and 
excipients. The reagents utilized in the proposed method are 
cheaper, readily available and the procedures do not involve any 
critical reaction conditions or tedious sample preparation. 
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